304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2020-07-29

Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, trastuzumab biosimilar
2020-06-24

Cooperation with Accord Upgraded: to Bring High Quality Products to More Patients
2020-06-16

Phase 3 Trial of Henlius Bevacizumab Biosimilar HLX04 in Metastatic Colorectal Cancer Met Study Primary Endpoint
2020-06-05

Exclusive Interview with Henlius Senior Vice President of Manufacturing & Engineering, Mrs Wei Huang
2020-05-31

Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)
2020-05-27

Henlius Received IND Approval for Denosumab Biosimilar HLX14 from NMPA
2020-04-24

First Patient in Overseas Trial Site Dosed in an International Multi-centre Phase 3 Study of Henlius Anti-PD-1 mAb HLX10 in ES-SCLC
2020-04-23

Henlius Receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
2020-04-23

First Patient in Overseas Trial Site Dosed in the Multi-centre International Phase 3 Study of Henlius Anti-PD-1 mAb for the Treatment of Lung Cancer

1
2
3
4
5